This section is intended for media and financial analysts
Search Press releases
27 Jun 2018
New UCB Research Showcases Value of CIMZIA® (certolizumab pegol) in Psoriasis and Highlights Unique Experiences and Real World Evidence for Key Patient Populations
New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey
New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases
UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
